FGF-23 and Secondary Hyperparathyroidism in Chronic Kidney Disease

Overview

Journal Nat Rev Nephrol

Specialty Nephrology

Date 2013 Jul 24

PMID 23877588

Citations 50

Authors

Justin Silver

Tally Naveh-Many

Affiliations

Soon will be listed here.

Abstract

The metabolic changes that occur in patients with chronic kidney disease (CKD) have a profound influence on mineral and bone metabolism. CKD results in altered levels of serum phosphate, vitamin D, calcium, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF-23); the increased levels of serum phosphate, PTH and FGF-23 contribute to the increased cardiovascular mortality in affected patients. FGF-23 is produced by osteocytes and osteoblasts and acts physiologically in the kidney to induce phosphaturia and inhibit the synthesis of 1,25-dihydroxyvitamin D3. PTH acts directly on osteocytes to increase FGF-23 expression. In addition, the high levels of PTH associated with CKD contribute to changes in bone remodelling that result in decreased levels of dentin matrix protein 1 and the release of low-molecular-weight fibroblast growth factors from the bone matrix, which stimulate FGF-23 transcription. A prolonged oral phosphorus load increases FGF-23 expression by a mechanism that includes local changes in the ratio of inorganic phosphate to pyrophosphate in bone. Other factors such as dietary vitamin D compounds, calcium, and metabolic acidosis all increase FGF-23 levels. This Review discusses the mechanisms by which secondary hyperparathyroidism associated with CKD stimulates bone cells to overexpress FGF-23 levels.

Citing Articles

Plant-Dominant Low-Protein Diets: A Promising Dietary Strategy for Mitigating Disease Progression in People with Chronic Kidney Disease-A Comprehensive Review.

Kaimori J, Sakaguchi Y, Oka T, Isaka Y Nutrients. 2025; 17(4).

PMID: 40004970 PMC: 11857991. DOI: 10.3390/nu17040643.

Young adults' circulating FGF23 and α-klotho and their relationship with habitual dietary acid load and phosphorus intake during growth.

Franco L, Derakhshandeh-Rishehri S, Nothlings U, Hartmann M, Herder C, Kalhoff H Sci Rep. 2024; 14(1):27784.

PMID: 39537770 PMC: 11561314. DOI: 10.1038/s41598-024-79636-0.

Carotid intima-media thickness, fibroblast growth factor 23, and mineral bone disorder in children with chronic kidney disease.

Palupi-Baroto R, Hermawan K, Murni I, Nurlita T, Prihastuti Y, Puspitawati I BMC Nephrol. 2024; 25(1):369.

PMID: 39433982 PMC: 11494757. DOI: 10.1186/s12882-024-03771-z.

Determination of the reference interval for urinary klotho to creatinine ratio of healthy dogs.

Marecakova N, Kacirova J, Tothova C, Madari A, Madar M, Farbakova J Front Vet Sci. 2024; 11:1423390.

PMID: 39113723 PMC: 11305118. DOI: 10.3389/fvets.2024.1423390.

Functional consequences of spatial, temporal and ligand bias of G protein-coupled receptors.

Toth A, Turu G, Hunyady L Nat Rev Nephrol. 2024; 20(11):722-741.

PMID: 39039165 DOI: 10.1038/s41581-024-00869-3.

References

Krieger N, Culbertson C, Kyker-Snowman K, Bushinsky D . Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone. Am J Physiol Renal Physiol. 2012; 303(3):F431-6. PMC: 3433868. DOI: 10.1152/ajprenal.00199.2012. View

Rowe P . Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr. 2012; 22(1):61-86. PMC: 3362997. DOI: 10.1615/critreveukargeneexpr.v22.i1.50. View

Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K . Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 2009; 77(3):232-8. DOI: 10.1038/ki.2009.414. View

Kobayashi K, Imanishi Y, Miyauchi A, Onoda N, Kawata T, Tahara H . Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol. 2005; 154(1):93-9. DOI: 10.1530/eje.1.02053. View

Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T . Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int. 2006; 70(12):2141-7. DOI: 10.1038/sj.ki.5002000. View

Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T . Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010; 78(10):975-80. DOI: 10.1038/ki.2010.313. View

Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T . PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010; 299(4):F882-9. DOI: 10.1152/ajprenal.00360.2010. View

Lomashvili K, Khawandi W, ONeill W . Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol. 2005; 16(8):2495-500. DOI: 10.1681/ASN.2004080694. View

Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson K . Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007; 195(1):125-31. DOI: 10.1677/JOE-07-0267. View

10.

Galitzer H, Ben-Dov I, Silver J, Naveh-Many T . Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2009; 77(3):211-8. DOI: 10.1038/ki.2009.464. View

11.

Wolf M . Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012; 82(7):737-47. PMC: 3434320. DOI: 10.1038/ki.2012.176. View

12.

Kolek O, Hines E, Jones M, LeSueur L, Lipko M, Kiela P . 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol. 2005; 289(6):G1036-42. DOI: 10.1152/ajpgi.00243.2005. View

13.

Wohrle S, Bonny O, Beluch N, Gaulis S, Stamm C, Scheibler M . FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res. 2011; 26(10):2486-97. DOI: 10.1002/jbmr.478. View

14.

Isakova T, Gutierrez O, Smith K, Epstein M, Keating L, Juppner H . Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant. 2010; 26(2):584-91. PMC: 3108359. DOI: 10.1093/ndt/gfq419. View

15.

Farrow E, Yu X, Summers L, Davis S, Fleet J, Allen M . Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011; 108(46):E1146-55. PMC: 3219119. DOI: 10.1073/pnas.1110905108. View

16.

Li Y, Amling M, Pirro A, Priemel M, Meuse J, Baron R . Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology. 1998; 139(10):4391-6. DOI: 10.1210/endo.139.10.6262. View

17.

Saini R, Kaneko I, Jurutka P, Forster R, Hsieh A, Hsieh J . 1,25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: evidence for primary and secondary mechanisms modulated by leptin and interleukin-6. Calcif Tissue Int. 2012; 92(4):339-53. PMC: 3595337. DOI: 10.1007/s00223-012-9683-5. View

18.

Bhattacharyya N, Wiench M, Dumitrescu C, Connolly B, Bugge T, Patel H . Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res. 2012; 27(5):1132-41. PMC: 7448291. DOI: 10.1002/jbmr.1546. View

19.

Ix J, Shlipak M, Wassel C, Whooley M . Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant. 2009; 25(3):993-7. PMC: 2902926. DOI: 10.1093/ndt/gfp699. View

20.

Yamashita H, Yamashita T, Miyamoto M, Shigematsu T, Kazama J, Shimada T . Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol. 2004; 151(1):55-60. DOI: 10.1530/eje.0.1510055. View